Table 2.
PCR uncorrected treatment responses for artemether-lumefantrine or dihydroartemisinin-piperaquine by day 28 and 42 days
| PCR-uncorrected Outcome | Lost/ withdrawn | Per-protocol analysis | Kaplan Meier Cure rate | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ETFa | LCFb | LTFc | ACPRd | |||||||
| No (%) | No | % (CI 95%) | No | % (CI 95%) | No | % (CI 95%) | No | % (CI 95%) | % (CI 95%) | |
| Kouvé site (Day 28) | ||||||||||
| ALe (n = 97) | 8 (8.2) | 0 | 0.0 (0.0–4.1) | 4 | 4.5 (1.2–11.1) | 6 | 6.7 (2.5–14.1) | 79 | 88.8 (80.3–94.5) | 88.9 (80.4–93.9) |
| DPf (n = 95) | 5 (5.3) | 0 | 0.0 (0.0–4.0) | 0 | 0.0 (0.0–4.0) | 1 | 1.1 (0.0–6.0) | 89 | 98.9 (94.0–100) | 98.9 (92.7–99.8) |
| Anié site (Day 28) | ||||||||||
| ALe (n = 82) | 3 (3.7) | 0 | 0.0 (0.0–4.6 | 4 | 5.1 (1.4–12.5 | 5 | 6.3 (2.1–14.2) | 70 | 88.6 (79.5–94.7) | 88.6 (79.3–93.9) |
| DPf (n = 83) | 7 (8.4) | 0 | 0.0 (0.0–4.7) | 1 | 1.3 (0–7.1) | 1 | 1.3 (0–7.1) | 74 | 97.4 (90.8–99.7 | 97.4 (89.9–99.3) |
| Kouvé site (Day 42) | ||||||||||
| ALe (n = 97) | 8 (8.2) | 0 | 0.0 (0.0–4.1) | 6 | 6.7 (2.5–14.1) | 10 | 11.2 (5.5–19.7) | 73 | 82.0 (72.5–89.4) | 82.2 (72.6–88.7) |
| DPf (n = 95) | 6 (6.3) | 0 | 0.0 (0.0–4.1) | 2 | 2.2 (0.3–7.9) | 5 | 5.6 (1.8–12.6) | 82 | 92.1 (84.5–96.8) | 92.3 (84.5–96.2) |
| Anié site (Day 42) | ||||||||||
| ALe (n = 82) | 3 (3.7) | 0 | 0.0 (0.0–4.6) | 5 | 6.3 (2.1–14.2) | 8 | 10.1 (4.5–19.0) | 66 | 83.5 (73.5–90.9) | 83.5 (73.4–90.1) |
| DPf (n = 83) | 7 (8.4) | 0 | 0.0 (0.0–4.7) | 1 | 1.3 (0.0–7.1) | 3 | 3.9 (0.8–11.1) | 72 | 94.7 (87.1–98.5) | 94.7 (86.6–98.0) |
aearly treatment failure
blate clincal failure
clate parasitological failure
dadequate clinical and parasitological response
eartemether-lumefantrine
fdihydroartemisinin-piperaquine